An aging asset has pushed AbbVie toward an ugly $63 billion Botox remedy. rob_cyran
AbbVie said on June 25 it had agreed to buy Allergan for about $63 billion, or $188.24 per share, a 45% premium to the closing price of Allergan’s shares on June 24. Allergan shareholders will receive 0.866 AbbVie shares and $120.30 in cash for each Allergan share held.
Following the close of the deal, AbbVie shareholders will own about 83% of the combined firm, and Allergan’s current owners approximately 17%. AbbVie said it expects cost cuts worth at least $2 billion per year before tax in the third year after the merger.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
AbbVie looks beyond Humira with $63 billion deal for Botox-maker AllerganDrugmaker AbbVie Inc said on Tuesday it would buy Botox-maker Allergan Plc for a...
Consulte Mais informação »
Allergan spikes 30% after AbbVie agrees to buy the Botox-maker for $63 billionAbbVie expects the acquisition to generate at least $2 billion in pre-tax synergies and cost reductions within three years.
Consulte Mais informação »
Abbvie is buying Allergan in a $63 billion pharma mega-dealThe biopharmaceuticals giant and drugmaker are combining to create a leader across immunology, neuroscience, eye care and other medical fields.
Consulte Mais informação »
AbbVie Strikes Deal to Buy Allergan for About $63 BillionAbbVie has reached a deal to buy Allergan for about $63 billion, as two big drugmakers bet a combination will deliver new sources of growth they have struggled to find on their own.
Consulte Mais informação »
AbbVie confirms deal to buy Allergan for 45% premium, valuing Allergan at $61.7 billionAbbVie Inc. confirmed Tuesday a deal to buy pharmaceutical company Allergan PLC , in a deal with equity value of $63 billion. Allergan's stock soared 30% in...
Consulte Mais informação »